Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Melanoma Drug Market
Interviewed Experts Lack Confidence in Malignant Melanoma Cancer
The new Pharmacor report entitled Malignant Melanoma finds that the launch of Bristol-Myers Squibb/Medarex's ipilimumab will significantly increase the size of the malignant melanoma drug market as sales of ipilimumab will grow at an annual rate of 17 percent from 2012 through 2017. Ipilimumab will account for nearly a quarter of malignant melanoma drug sales in 2012 and just over a third of sales in 2017.
The report also finds that, as a result of recently published data on vaccines in malignant melanoma, interviewed experts lack confidence in the vaccine drug class. Among cancer vaccines that had been previously regarded as promising emerging agents, Progenics' GM2-KLH21 has recently shown to be detrimental in early stage malignant melanoma.
"The incidence of malignant melanoma is rising rapidly," said Marcus Hoyle, analyst at Decision Resources. "A huge unmet need in the treatment of this cancer remains for the development of therapies that can prolong overall survival in the advanced stages as prognosis at this stage is poor with a median overall survival of six to nine months."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.